acetylcholine release: nootropics and compounds | sci-wiki

GSK189254

GlaxoSmithKline built GSK189254 out of a benzazepine chemical series distinct from the imidazole-based H3 antagonists that came before it, and it turned into one of the field's most cited cognition tool compounds. It binds human H3 receptors with subnanomolar affinity and more than 10,000-fold selectivity over other targets tested, and PET-style binding studies confirmed it engages H3 receptors directly in postmortem Alzheimer's disease brain tissue. In rodents it raised acetylcholine, noradrenaline, and dopamine release in the cortex and hippocampus and improved performance across passive avoidance, water maze, object recognition, and attentional set-shifting tasks, a strong enough preclinical package that GSK explored it for Alzheimer's-related cognitive symptoms; it never emerged as a named clinical program, and the compound is now used mainly as a research standard rather than a drug candidate.

reference

Nootropic

Linopirdine

Linopirdine took a completely different route to boosting acetylcholine than anything else in this collection; instead of blocking the enzyme that breaks ACh down, DuPont built it to block KCNQ2/KCNQ3 potassium channels, the so-called M-channel, which in turn triggers broad neurotransmitter release, acetylcholine included, across the brain. Preclinical work in the late 1980s looked strong enough that DuPont pushed it into Alzheimer's clinical trials, but the results in patients were equivocal; the drug needed high doses to meaningfully block the M-current, and those doses caused cholinergic overstimulation side effects like tremor. The program was ultimately discontinued, but linopirdine's real legacy is scientific rather than commercial, it became the founding tool compound for an entire generation of KCNQ channel research, directly enabling more selective descendants like XE-991 and eventually helping validate KCNQ as a target that led to the anticonvulsant retigabine.

reference

Nootropic

T-588

T-588 came out of Toyama Chemical in Japan as a multi-target cognitive enhancer built for the vascular-dementia and post-stroke cognitive-impairment niche that Japanese pharma researched heavily in the 1990s, a market segment Western companies mostly ignored. Rather than hitting one clean receptor, it increased acetylcholine and noradrenaline release in the cortex and hippocampus, blocked an outward potassium current in CA1 neurons, and protected cerebellar granule cells from glutamate excitotoxicity, a genuinely broad-spectrum profile aimed at both boosting transmission and shielding neurons from ischemic damage. It compensated for scopolamine-induced learning impairment and improved working memory after simulated cerebral ischemia in rodents, but like most Japanese vascular-cognition compounds of its era, it never crossed into Western regulatory pipelines and faded from view once academic interest moved to other neuroprotective targets.

reference